Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) shares fell 3.7% during mid-day trading on Tuesday . The stock traded as low as $12.07 and last traded at $12.07. 227 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 33,381 shares. The stock had previously closed at $12.54.
Finch Therapeutics Group Stock Performance
The company has a market cap of $19.39 million, a PE ratio of -1.19 and a beta of 1.25. The stock’s 50-day simple moving average is $6.34 and its 200 day simple moving average is $3.59.
Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($3.01) EPS for the quarter.
Institutional Investors Weigh In On Finch Therapeutics Group
About Finch Therapeutics Group
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Read More
- Five stocks we like better than Finch Therapeutics Group
- How to Choose Top Rated Stocks
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- Election Stocks: How Elections Affect the Stock Market
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.